WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2002003792) TRANSGENIC MICE CONTAINING TARGETED PROTEASE INHIBITOR GENE DISRUPTIONS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2002/003792    International Application No.:    PCT/US2001/021824
Publication Date: 17.01.2002 International Filing Date: 10.07.2001
Chapter 2 Demand Filed:    04.02.2002    
IPC:
C07K 14/81 (2006.01), C12N 15/85 (2006.01)
Applicants: DELTAGEN, INC. [US/US]; 740 Bay Road Redwood City, CA 94063 (US) (For All Designated States Except US).
ALLEN, Keith, D. [US/US]; (US) (For US Only)
Inventors: ALLEN, Keith, D.; (US)
Agent: BURKE, John, E. à; Deltagen, Inc. 740 Bay Road Redwood City, CA 94063 (US).
LAPIZ, Mariette, A.; DeltaGen, Inc. 740 Bay Road Redwood City, CA 94063 (US)
Priority Data:
60/217,783 11.07.2000 US
60/217,625 11.07.2000 US
60/217,329 11.07.2000 US
60/217,327 11.07.2000 US
60/218,017 12.07.2000 US
60/249,410 15.11.2000 US
60/262,126 16.01.2001 US
60/300,896 26.06.2001 US
Title (EN) TRANSGENIC MICE CONTAINING TARGETED PROTEASE INHIBITOR GENE DISRUPTIONS
(FR) SOURIS TRANSGENIQUES CONTENANT DES DISRUPTIONS DE GENES CIBLES D'INHIBITEURS DE PROTEINASES
Abstract: front page image
(EN)The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a target protease inhibitor gene, more specifically a systatin or a stefin, a serine protease inhibitor or WDNM1. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
(FR)L'invention concerne des animaux transgéniques, ainsi que des compositions et des procédés relatifs à la caractérisation de la fonction génique. Elle concerne, plus particulièrement, des souris transgéniques contenant des mutations de gène ciblé d'inhibiteur de protéinase. Ces souris transgéniques sont utiles en tant que modèles de maladies et servent à identifier des agents modulant l'expression et la fonction géniques et à traiter potentiellement différentes maladies et états pathologiques.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)